Form 4: Palisade Bio Chief Medical Officer Mitchell Jones Reports Stock Transactions

Mitchell Jones, Chief Medical Officer of Palisade Bio, Inc., reports the vesting and settlement of restricted stock units resulting in the acquisition and disposal of common stock to cover tax obligations.

Summary

• On May 28, 2024, Mitchell Jones, the Chief Medical Officer of Palisade Bio, Inc., reported transactions involving the company's common stock.
• These transactions involved the vesting and settlement of restricted stock units (RSUs) granted on September 5, 2023, and November 21, 2023.
• A total of 2,735 shares were issued upon the vesting of RSUs granted on September 5, 2023.
• Additionally, 810 shares were withheld to cover tax obligations related to these vested RSUs, priced at $4.76 per share.
• Another 1,555 shares were issued upon the vesting of RSUs granted on November 21, 2023.
• 461 shares were withheld to cover tax obligations related to these vested RSUs, also priced at $4.76 per share.
• Following these transactions, Jones directly owns 3,852 shares of Palisade Bio common stock.
• The Compensation Committee of the Issuer accelerated and vested all remaining restricted stock units subject to the awards on May 28, 2024.

Sentiment

Score: 5

Explanation: The document is a standard SEC filing detailing stock transactions, with neutral sentiment.

Industry Context

This Form 4 filing is a routine disclosure required by the SEC for insiders of publicly traded companies, providing transparency into their transactions in the company's stock.

Stakeholder Impact

• The transactions may have a minor impact on shareholders due to the change in insider ownership.
• Employees holding RSUs may be affected by the vesting schedule and tax implications.

Key Dates

Keywords

Palisade Bio, Mitchell Jones, Chief Medical Officer, stock transactions, restricted stock units, RSUs, common stock, vesting, settlement, tax withholding